J. M. Tusell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
J. M. Tusell has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
E. Gorina
Research and Development Department, Bayer, Barcelona, Spain
1 shared publicationF. Querol
Congenital Coagulopathy Unit, University Hospital La Fe and Physiotherapy, Department of the University of Valencia
1 shared publicationJ. A. Aznar
Congenital Coagulopathy Unit, University Hospital La Fe and Physiotherapy, Department of the University of Valencia
1 shared publicationM. Moreno
University Hospital Virgen de la Arrixaca, Murcia
1 shared publicationM. Quintana
University Hospital La Paz, Madrid
1 shared publicationR. Pérez‐Bianco
Hospital Vall d'Hebron, Barcelona, Spain, Academia Nacional de Medicina, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 16 May 2002
- Published by Wiley in Haemophilia
- Vol. 8 (3) , 183-188
Prophylaxis in developed and in emerging countries
The significant progress made in recent years in the safety and efficacy of both plasma‐derived and recombinant factor concentrates has allowed treatment programmes to be developed that go beyond the simply curative or the treatment of the consequences of the disease (episodic or on‐demand treatment), enabling the criteria of preventative medicine to be applied to congenital bleeding disorders. The aim of these programmes is to achieve constant, minimum levels of factor in patients above 1 or 2%, thereby converting severe haemophilia into moderate haemophilia.
- 16 May 2002
- Published by Wiley in Haemophilia
- Vol. 8 (3) , 183-188
Prophylaxis in developed and in emerging countries
The significant progress made in recent years in the safety and efficacy of both plasma‐derived and recombinant factor concentrates has allowed treatment programmes to be developed that go beyond the simply curative or the treatment of the consequences of the disease (episodic or on‐demand treatment), enabling the criteria of preventative medicine to be applied to congenital bleeding disorders. The aim of these programmes is to achieve constant, minimum levels of factor in patients above 1 or 2%, thereby converting severe haemophilia into moderate haemophilia.
- 1 March 2002
- Published by Wiley in Haemophilia
- Vol. 8 (s2) , 38-42
Results of an orthopaedic survey in young patients with severe haemophilia in Spain
Summary. This paper outlines the results obtained in a cross‐sectional study of a group of young patients with severe haemophilia A and B. The primary aim of the study was to ascertain the level of orthopaedic complications in the group, the effects that these complications have on quality of life, and the medical resources used on these patients. The secondary aim was to relate their current orthopaedic state to the type of treatment received before the study. The study was carried out in 11 hospitals in Spain, where 70 severe haemophilia patients (factor VIII [FVIII] < 2%), with an average age of 21.6 and a median age of 22, and no inhibitors, were monitored. The percentage of patients suffering from articular complaints was 84.3% and 85.7% according to the Gilbert and Petterson scales, respectively. Furthermore, pain was reported in 16.1% of joints, most frequently in ankles. Using the SF‐36 Health Survey, patients were observed to have a poorer quality of life relative to healthy controls. Despite high levels of both the coagulant factor given to patients and the financial resources dedicated to their treatment, the type of treatment (on demand and/or as secondary prophylaxis) provided to the young adults was found to be incapable of preventing haemophilic arthropathy and subsequent negative quality of life consequences.
- 1 March 2002
- Published by Wiley in Haemophilia
- Vol. 8 (s2) , 38-42
Results of an orthopaedic survey in young patients with severe haemophilia in Spain
Summary. This paper outlines the results obtained in a cross‐sectional study of a group of young patients with severe haemophilia A and B. The primary aim of the study was to ascertain the level of orthopaedic complications in the group, the effects that these complications have on quality of life, and the medical resources used on these patients. The secondary aim was to relate their current orthopaedic state to the type of treatment received before the study. The study was carried out in 11 hospitals in Spain, where 70 severe haemophilia patients (factor VIII [FVIII] < 2%), with an average age of 21.6 and a median age of 22, and no inhibitors, were monitored. The percentage of patients suffering from articular complaints was 84.3% and 85.7% according to the Gilbert and Petterson scales, respectively. Furthermore, pain was reported in 16.1% of joints, most frequently in ankles. Using the SF‐36 Health Survey, patients were observed to have a poorer quality of life relative to healthy controls. Despite high levels of both the coagulant factor given to patients and the financial resources dedicated to their treatment, the type of treatment (on demand and/or as secondary prophylaxis) provided to the young adults was found to be incapable of preventing haemophilic arthropathy and subsequent negative quality of life consequences.